• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

儿科血小板减少症患者血小板输注反应:发生率、临床变量。

Responsiveness to Platelet Transfusions in Pediatric Patients with Thrombocytopenia: Incidence, Clinical Variables.

出版信息

Clin Lab. 2023 Jul 1;69(7). doi: 10.7754/Clin.Lab.2022.221231.

DOI:10.7754/Clin.Lab.2022.221231
PMID:37436388
Abstract

BACKGROUND

Refractoriness to platelet transfusion has not been adequately studied in pediatric patients with thrombocytopenia. Our objectives were: (1) to describe the practice of platelet transfusion in pediatric patients with thrombocytopenia of various etiologies; (2) to assess the responsiveness to platelet transfusions and clinical variables affecting platelet transfusions response; and (3) to evaluate incidence of PTR.

METHODS

A retrospective study included pediatric patients with thrombocytopenia admitted to a tertiary children's hospital who received ≥ 1 platelet transfusion during hospitalization. Responsiveness was measured by corrected count increment (CCI), poor platelet transfusion response (PPTR), and platelet transfusion refractoriness (PTR).

RESULTS

A total of 334 patients were eligible for the study and received 1,164 transfusions, with a median of 2 (IQR: 1 - 5) platelet transfusions. Patients admitted with hematologic malignancies had the highest median number of platelet transfusions (5, IQR: 4 - 10). The median CCI of 1,164 platelet post-transfusions was 17.0 (IQR: 9.4 - 24.6) and the incidence of PPTR was 11.9%. Patients admitted with ITP had the lowest median CCI (7.6, IQR: 1.0 - 12.5) and the highest incidence of PPTR (36.4%, 8/22). Older age of platelet components, low doses of platelet transfusion, increasing number of platelet transfusions (≥ 5), splenomegaly, bleeding, DIC, shock, ECMO supported, and HLA antibody-positive were independent risk factors for PPTR. Finally, the incidence of PTR was 11.4%.

CONCLUSIONS

Practical experience of clinicians regarding the use of apheresis platelets in pediatric patients is determined. Highlight that PTR is not a low probability event when apheresis platelets are received in pediatric patients.

摘要

背景

血小板减少症患儿的血小板输注抵抗尚未得到充分研究。我们的目标是:(1)描述各种病因所致血小板减少症患儿血小板输注的实践情况;(2)评估血小板输注的反应性及影响血小板输注反应的临床变量;(3)评估血小板输注无效(PTR)的发生率。

方法

本回顾性研究纳入了因血小板减少症而入住三级儿童医院的儿科患者,这些患者在住院期间至少接受过 1 次血小板输注。通过校正血小板计数增加值(CCI)、血小板输注不良反应(PPTR)和血小板输注抵抗(PTR)来衡量反应性。

结果

共有 334 例患者符合入选标准,并接受了 1164 次输注,中位数为 2(IQR:1-5)次血小板输注。因血液病而入院的患者接受的血小板输注中位数最高(5,IQR:4-10)。1164 次血小板输注后的中位数 CCI 为 17.0(IQR:9.4-24.6),PPTR 的发生率为 11.9%。因 ITP 而入院的患者 CCI 中位数最低(7.6,IQR:1.0-12.5),PPTR 的发生率最高(36.4%,8/22)。血小板成分的年龄较大、血小板输注剂量较低、血小板输注次数(≥5 次)增加、脾肿大、出血、DIC、休克、ECMO 支持和 HLA 抗体阳性是 PPTR 的独立危险因素。最后,PTR 的发生率为 11.4%。

结论

确定了临床医生在儿科患者中使用单采血小板的实际经验。强调当儿科患者接受单采血小板时,PTR 并不是低概率事件。

相似文献

1
Responsiveness to Platelet Transfusions in Pediatric Patients with Thrombocytopenia: Incidence, Clinical Variables.儿科血小板减少症患者血小板输注反应:发生率、临床变量。
Clin Lab. 2023 Jul 1;69(7). doi: 10.7754/Clin.Lab.2022.221231.
2
Exploration of risk factors of platelet transfusion refractoriness and its impact on the prognosis of hematopoietic stem cell transplantation: a retrospective study of patients with hematological diseases.血小板输注无效的危险因素探讨及其对造血干细胞移植预后的影响:血液病患者的回顾性研究。
Platelets. 2023 Dec;34(1):2229905. doi: 10.1080/09537104.2023.2229905.
3
Post-transfusion platelet responses in critically ill cancer patients with hypoproliferative thrombocytopenia.危重症癌症伴低增生性血小板减少症患者的输血后血小板反应。
Transfusion. 2020 Feb;60(2):275-284. doi: 10.1111/trf.15596. Epub 2019 Nov 14.
4
Platelet transfusion practice and platelet refractoriness for a cohort of pediatric oncology patients: A single-center study.血小板输注实践和儿科肿瘤患者血小板输注抵抗:一项单中心研究。
Pediatr Blood Cancer. 2020 Dec;67(12):e28734. doi: 10.1002/pbc.28734. Epub 2020 Sep 25.
5
Safety and efficacy of transfusions of autologous cryopreserved platelets derived from recombinant human thrombopoietin to support chemotherapy-associated severe thrombocytopenia: a randomised cross-over study.输注重组人血小板生成素来源的自体冻存血小板以支持化疗相关严重血小板减少症的安全性和有效性:一项随机交叉研究。
Lancet. 2002 Jun 22;359(9324):2145-52. doi: 10.1016/S0140-6736(02)09090-6.
6
Use of platelet transfusions prior to lumbar punctures or epidural anaesthesia for the prevention of complications in people with thrombocytopenia.在腰椎穿刺或硬膜外麻醉前使用血小板输注以预防血小板减少症患者的并发症。
Cochrane Database Syst Rev. 2018 Apr 30;4(4):CD011980. doi: 10.1002/14651858.CD011980.pub3.
7
Evaluation of platelet function using the in vitro bleeding time and corrected count increment of transfused platelets. Comparison between platelet concentrates derived from pooled buffy coates and apheresis.使用体外出血时间和输注血小板校正计数增加值评估血小板功能。比较来自混合白膜层和单采血小板的浓缩血小板。
Vox Sang. 1996;70(2):69-75. doi: 10.1111/j.1423-0410.1996.tb01296.x.
8
Preoperative platelet transfusions: A retrospective review of pediatric patients with thrombocytopenia, 2011-2016.术前血小板输注:2011-2016 年血小板减少症儿科患者的回顾性研究。
J Pediatr Surg. 2021 Sep;56(9):1657-1660. doi: 10.1016/j.jpedsurg.2021.04.027. Epub 2021 May 2.
9
Platelet refractoriness and alloimmunization in pediatric oncology and bone marrow transplant patients.儿科肿瘤学和骨髓移植患者中的血小板不应答和同种免疫
Transfusion. 1995 Aug;35(8):645-52. doi: 10.1046/j.1537-2995.1995.35895357895.x.
10
Therapeutic Efficacy of Platelet Transfusion and Analysis of Influencing Factors in 364 patients.364 例患者血小板输注的治疗效果及影响因素分析。
Acta Haematol. 2023;146(3):214-219. doi: 10.1159/000529542. Epub 2023 Feb 9.